Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
The Food and Drug Administration may approve the next site-agnostic treatment in August.
A three-pronged approach could offer hope for people with hard-to-treat advanced pancreatic cancer.
A new type of immunotherapy shows promising activity against cancers caused by human papillomavirus (HPV).
Could new cancer drugs restore immune responses against HIV?
Removal of the primary breast tumor may be warranted in women who respond well to targeted therapies.
Changing gut bacteria to improve treatment response may be the next frontier in immunotherapy.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.
Large international study sees no detrimental outcomes for mothers or babies.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
Around 90% of people treated with the immunomodulator did not develop cancer.
Recently approved CDK4/6 inhibitor plus hormone therapy extends overall survival by about a third.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.